Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
TOP Ships Inc.

Start price
Target price
Perf. (%)
€20.80
14.12.20
€40.00
28.85%
11.01.21

Could be very worthwhile Investment >20% year
buy
InVivo Therapeutics Holdings

Start price
Target price
Perf. (%)
€13.00
14.12.20
€25.00
14.12.21
71.15%
11.01.21

Could be worthwhile Investment >10% per year
vTv Therapeutics Inc

Start price
Target price
Perf. (%)
€2.30
12.12.20
€1.00
12.12.21
-14.22%
26.06.21

Risky Investment
Revenue decline > 20% expected
EBIT decline > 20% expected
overvalued
Sonoma Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€6.90
12.12.20
€3.00
12.12.21
-8.48%
26.06.21

Risky Investment
Revenue decline > 20% expected
Decining EBIT margin than peer group
EBIT decline > 20% expected
aTyr Pharma Inc

Start price
Target price
Perf. (%)
€3.78
12.12.20
€2.00
12.12.21
4.76%
26.06.21

Risky Investment
Revenue decline > 20% expected
EBIT decline > 20% expected
Decining EBIT margin than peer group
Immutep LTD ADR

Start price
Target price
Perf. (%)
€5.85
10.12.20
€5.00
-20.34%
10.12.20

Could be very worthwhile Investment >20% year
buy
BP plc

Start price
Target price
Perf. (%)
€3.03
07.12.20
€5.80
07.12.21
6.34%
25.01.21

Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
buy
BP plc

Start price
Target price
Perf. (%)
€3.03
07.12.20
€5.80
07.12.21
6.34%
25.01.21

Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
buy
Bio Path Holdings

Start price
Target price
Perf. (%)
€2.80
04.12.20
-
04.12.21
-81.43%
05.12.21

Probably not worthwhile Investment
Revenue decline/stagnation expected
Lower EBIT Margin than peer group
High valuation
Ever-Glory International

Start price
Target price
Perf. (%)
€6.05
03.12.20
-
-55.70%
10.12.20

Risky Investment
buy
Larimar Therapeutics Inc.

Start price
Target price
Perf. (%)
€17.12
01.12.20
€20.00
01.12.21
5.26%
14.12.20

Could be worthwhile Investment >10% per year
buy
Inpixon

Start price
Target price
Perf. (%)
€69.38
30.11.20
€150.00
-7.03%
14.12.20

Could be worthwhile Investment >10% per year
buy
TOP Ships Inc.

Start price
Target price
Perf. (%)
€19.60
30.11.20
€40.00
6.12%
14.12.20

Could be very worthwhile Investment >20% year
buy
Supercom

Start price
Target price
Perf. (%)
€1.46
30.11.20
€2.00
30.11.21
-42.12%
14.12.20

Could be worthwhile Investment >10% per year
Capable Management
Bad culture
Little innovation
buy
HelloFresh SE

Start price
Target price
Perf. (%)
€49.62
29.11.20
€108.00
29.11.21
87.51%
30.11.21

Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
Bad rating
Baidu Inc. A ADR

Start price
Target price
Perf. (%)
€116.80
28.11.20
-
28.11.21
115.33%
19.02.21

ROE higher than 15% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Small challenges to pay loans and raise capital
Baidu Inc. A ADR

Start price
Target price
Perf. (%)
€116.80
28.11.20
-
28.11.21
115.33%
19.02.21

ROE higher than 15% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Small challenges to pay loans and raise capital
Fuel Techs Inc.

Start price
Target price
Perf. (%)
€4.88
24.11.20
-
24.11.21
-68.65%
25.11.21

Probably not worthwhile Investment
Englobal

Start price
Target price
Perf. (%)
€2.10
24.11.20
-
24.11.21
11.43%
02.06.21

Probably not worthwhile Investment
buy
Aemetis Inc.

Start price
Target price
Perf. (%)
€1.74
23.11.20
€15.00
23.11.21
796.55%
24.11.21

Could be very worthwhile Investment >20% year
buy
Kazia Therapeutics ADR

Start price
Target price
Perf. (%)
€10.50
19.11.20
-
19.11.21
-28.57%
19.11.21

Risky Investment
Socket Mobile Inc.

Start price
Target price
Perf. (%)
€2.40
19.11.20
-
19.11.21
103.58%
20.11.21

Revenue growth >5% per year expected
EBIT growth >5% per year expected
Probably not worthwhile Investment
Lower EBIT Margin than peer group
Dixie Group Inc.

Start price
Target price
Perf. (%)
€1.61
19.11.20
-
19.11.21
222.98%
20.11.21

Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
buy
Aptevo Therapeutics Inc.

Start price
Target price
Perf. (%)
€42.00
19.11.20
€50.00
19.11.21
-67.07%
07.11.21

Could be very worthwhile Investment >20% year
buy
Socket Mobile Inc.

Start price
Target price
Perf. (%)
€2.80
18.11.20
€4.00
18.11.21
-25.00%
28.11.20

Could be worthwhile Investment >10% per year
Fair valuation
Bad rating
Few uniques